Cargando…
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have provided definitions for primary and secondary resista...
Autores principales: | Tawbi, Hussein A, Sullivan, Ryan J, Feltquate, David, LaVallee, Theresa, Rizvi, Naiyer A, Sharon, Elad, Sosman, Jeffrey, Kluger, Harriet M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373737/ https://www.ncbi.nlm.nih.gov/pubmed/37487665 http://dx.doi.org/10.1136/jitc-2023-007309 |
Ejemplares similares
-
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023) -
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023) -
Correction: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Publicado: (2023) -
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023) -
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)